Anti-HLA-DR Beta chain Antibody, Non-Fucosylated (BioBet-999ZP) (CAT#: BioBet-999ZP) Datasheet

HLA-DR βchain

Human Leukocyte Antigen-DR Beta chain

The DR β-chain is encoded by 4 loci, however no more than 3 functional loci are present in a single individual, and no more than two on a single chromosome. Sometimes an individual may only possess 2 copies of the same locus, DRB1*. The HLA-DRB1 locus is ubiquitous and encodes a very large number of functionally variable gene products (HLA-DR1 to HLA-DR17). The HLA-DRB3 locus encodes the HLA-DR52 specificity, is moderately variable and is variably associated with certain HLA-DRB1 types. The HLA-DRB4 locus encodes the HLA-DR53 specificity, has some variation, and is associated with certain HLA-DRB1 types. The HLA-DRB5 locus encodes the HLA-DR51 specificity, which is typically invariable, and is linked to the HLA-DR2 types.

HLA-DR Beta chain; Human Leukocyte Antigen-DR Beta chain; DR Beta chain

Golgi apparatus, Plasma membrane, Endosome, Lysosome, Endoplasmic reticulum

Diseases associated with HLA-DRB1 include Sarcoidosis 1 and Multiple Sclerosis.

Its related pathways are TCR Signaling (Qiagen) and Tuberculosis.

The antigen presents the beta chain of the major histocompatibility complex II (MHCII) molecule. Complex with HLA-DRA chain, display antigen peptides on professional antigen-presenting cells (APCs) for recognition by -beta T cell receptor (TCR) on hla-drb1-restricted cd4-positive T cells. This will guide antigen-specific T helper effector functions, including antibody-mediated immune response and macrophage activation, and ultimately eliminate infectious agents and transformed cells. Typical extracellular peptide antigens of 10 to 30 amino acids are produced by proteolysis of phosphorylated antigens in lysosomes. In the tumor microenvironment, antigen peptides mainly produced by tumor cell apoptotic APCs may be produced by the macropinocytosis of phagocytosis of apoptotic tumor cells or secretion of tumor proteins. The selection of immunodominant epitopes follows two processing modes: for pathogen-derived antigen peptides, "combine first and then cleave"; for autoantigens/self peptides, "cleave first and then bind". The anchor residue at position 1 at the n-terminus of peptides is usually a large hydrophobic residue, which is necessary for high-affinity interactions with MHCII molecules.

Immune System antibody

Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4

BioBet-999ZP

Human

Human

1D09C3 is a human monoclonal IgG4-type antibody against human leukocyte antigen-DR (HLA-DR) which has demonstrated pro-apoptotic activity against lymphoid tumors in vitro and in vivo. 1D09C3 could be administered safely in patients with advanced B cell malignancies.

B-cell malignancies

B-cell malignancies